
ImmunityBio
- Active openings
- 10+
- US-based roles
- 10+
- Remote-friendly
- 2
- Last updated
- 2026-11-16
What ImmunityBio is hiring for
Open positions
10+ active
Contracts Administrator - FinanceEl Segundo CA Mariposa, USNov 16
Specialist, Regulatory Pharmacologist - PromotionsSummit, NJNov 13
Scientist I, Analytical Development - Process SciencesLouisville, CONov 12
National Account Director - NortheastUSNov 11
Research Associate I, Analytical DevelopmentLouisville, CONov 10
About ImmunityBio
Claim to unlockMission, culture, and benefits - visible once this page is claimed and verified.
Updates
ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026
New U.S. Survey of Military Service Members and Veterans with Non-Muscle Invasive Bladder Cancer Reveals 53% Were Diagnosed at Age 50 or Younger and Barriers to Care
ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million
ImmunityBio and Rafa Announce Israeli Ministry of Health Approval of ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
ImmunityBio Announces ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 Trial
ImmunityBio Announces First Patients in Europe Treated with ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ